$COEP
Coeptis Therapeutics Holdings, Inc. Stock $coep

$coep Overview Financials Valuation SEC Filings Company Website

2024 Q1 Form 10-K Financial Statement

#000168316824001685 Filed on March 26, 2024

Income Statement

Concept	2024 Q1	2023 Q4	2023
Revenue	$0.00	$0.00	$0.00
YoY Change
Cost Of Revenue	$0.00		$0.00
YoY Change
Gross Profit	$0.00		$0.00
YoY Change
Gross Profit Margin
Selling, General & Admin		$2.353M	$14.82M
YoY Change			-56.63%
% of Gross Profit
Research & Development	$777.1K	$1.013M	$6.668M
YoY Change	2918.92%		31825.31%
% of Gross Profit
Depreciation & Amortization	$250.2K	$250.3K	$1.001M
YoY Change	-0.04%	-75.0%	-0.01%
% of Gross Profit
Operating Expenses	$2.922M	$3.366M	$21.49M
YoY Change	-54.69%	-90.16%	-37.15%
Operating Profit	-$2.922M		-$21.49M
YoY Change	-54.69%		-37.15%
Interest Expense	$200.5K	-$192.7K	$460.1K
YoY Change	538.21%		110.64%
% of Operating Profit
Other Income/Expense, Net	-$79.01K	-$196.9K	-$235.5K
YoY Change	-94.43%	-94.17%	-93.03%
Pretax Income	-$3.001M	-$3.756M	-$21.27M
YoY Change	-61.85%	-90.0%	-43.4%
Income Tax	$0.00	$0.00	$0.00
% Of Pretax Income
Net Earnings	-$3.001M	-$3.756M	-$21.27M
YoY Change	-61.85%	-90.0%	-43.4%
Net Earnings / Revenue
Basic Earnings Per Share	-$0.08		-$0.83
Diluted Earnings Per Share	-$0.08	-$0.11	-$0.83
COMMON SHARES
Basic Shares Outstanding	36.09M shares	34.11M shares	25.69M shares
Diluted Shares Outstanding	35.54M shares		25.69M shares

Balance Sheet

Concept	2024 Q1	2023 Q4	2023
SHORT-TERM ASSETS
Cash & Short-Term Investments		$1.469M	$1.469M
YoY Change		-61.25%	-61.25%
Cash & Equivalents	$1.029M	$1.469M
Short-Term Investments
Other Short-Term Assets		$241.6K	$241.6K
YoY Change		69.71%	69.71%
Inventory
Prepaid Expenses	$242.0K	$241.6K
Receivables		$3.500M	$3.500M
Other Receivables		$38.98K	$38.98K
Total Short-Term Assets	$6.880M	$5.250M	$5.250M
YoY Change	202.28%	33.18%	33.18%
LONG-TERM ASSETS
Property, Plant & Equipment	$11.10K	$108.9K	$108.9K
YoY Change	-9.3%	768.12%	52.36%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets		$2.713M	$2.713M
YoY Change		-30.49%	-30.49%
Total Long-Term Assets	$2.515M	$2.821M	$2.821M
YoY Change	-31.41%	-29.0%	-29.0%
TOTAL ASSETS
Total Short-Term Assets	$6.880M	$5.250M	$5.250M
Total Long-Term Assets	$2.515M	$2.821M	$2.821M
Total Assets	$9.394M	$8.071M	$8.071M
YoY Change	58.09%	1.96%	1.96%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$1.366M	$1.420M	$1.420M
YoY Change	463.37%	1333.74%	1333.75%
Accrued Expenses	$719.0K	$594.0K	$594.0K
YoY Change	250.68%	226.38%	165.63%
Deferred Revenue
YoY Change
Short-Term Debt		$0.00	$0.00
YoY Change
Long-Term Debt Due		$975.0K	$975.0K
YoY Change		-35.0%	-35.0%
Total Short-Term Liabilities	$4.301M	$2.989M	$2.989M
YoY Change	117.35%	63.98%	63.98%
LONG-TERM LIABILITIES
Long-Term Debt	$150.0K	$150.0K	$150.0K
YoY Change	0.0%	0.0%	0.0%
Other Long-Term Liabilities		$618.4K	$618.4K
YoY Change		-45.74%	-45.74%
Total Long-Term Liabilities	$733.6K	$768.4K	$768.4K
YoY Change	-72.6%	-40.42%	-40.42%
TOTAL LIABILITIES
Total Short-Term Liabilities	$4.301M	$2.989M	$2.989M
Total Long-Term Liabilities	$733.6K	$768.4K	$768.4K
Total Liabilities	$5.035M	$3.757M	$3.757M
YoY Change	8.13%	20.72%	20.72%
SHAREHOLDERS EQUITY
Retained Earnings	-$90.36M	-$87.36M
YoY Change	22.76%	32.88%
Common Stock	$3.643K	$3.533K
YoY Change	73.97%	80.53%
Preferred Stock
YoY Change
Treasury Stock (at cost)	$0.00	$0.00
YoY Change
Treasury Stock Shares
Shareholders Equity	$4.359M	$4.314M	$4.314M
YoY Change
Total Liabilities & Shareholders Equity	$9.394M	$8.071M	$8.071M
YoY Change	58.09%	1.96%	1.96%

Cashflow Statement

Concept	2024 Q1	2023 Q4	2023
OPERATING ACTIVITIES
Net Income	-$3.001M	-$3.756M	-$21.27M
YoY Change	-61.85%	-90.0%	-43.4%
Depreciation, Depletion And Amortization	$250.2K	$250.3K	$1.001M
YoY Change	-0.04%	-75.0%	-0.01%
Cash From Operating Activities	-$1.902M	-$1.694M	-$7.240M
YoY Change	12.94%	-48.85%	86.79%
INVESTING ACTIVITIES
Capital Expenditures
YoY Change
Acquisitions
YoY Change
Other Investing Activities			$0.00
YoY Change
Cash From Investing Activities	-$100.0K		$0.00
YoY Change
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net			$5.492M
YoY Change			67.89%
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	$1.563M	1.751M	4.917M
YoY Change		-96.35%	-10.39%
NET CHANGE
Cash From Operating Activities	-$1.902M	-1.694M	-7.240M
Cash From Investing Activities	-$100.0K		0.000
Cash From Financing Activities	$1.563M	1.751M	4.917M
Net Change In Cash	-$439.9K	57.63K	-2.322M
YoY Change	-73.89%	-97.12%	-244.08%
FREE CASH FLOW
Cash From Operating Activities	-$1.902M	-$1.694M	-$7.240M
Capital Expenditures
Free Cash Flow
YoY Change

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2023	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2023
CY2023	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	FY
CY2023	dei	Entity Central Index Key EntityCentralIndexKey	0001759186
CY2023Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2022Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2022	us-gaap	Stock Repurchased And Retired During Period Value StockRepurchasedAndRetiredDuringPeriodValue		usd
CY2023	dei	Document Type DocumentType	10-K
CY2023	dei	Document Annual Report DocumentAnnualReport	true
CY2023	dei	Document Period End Date DocumentPeriodEndDate	2023-12-31
CY2023	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2023	dei	Entity File Number EntityFileNumber	001-39669
CY2023	dei	Entity Registrant Name EntityRegistrantName	Coeptis Therapeutics Holdings, Inc.
CY2023	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
CY2023	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	98-1465952
CY2023	dei	Entity Address Address Line1 EntityAddressAddressLine1	105 Bradford Rd
CY2023	dei	Entity Address Address Line2 EntityAddressAddressLine2	Suite 420
CY2023	dei	Entity Address City Or Town EntityAddressCityOrTown	Wexford
CY2023	dei	Entity Address State Or Province EntityAddressStateOrProvince	PA
CY2023	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	15090
CY2023	dei	City Area Code CityAreaCode	724
CY2023	dei	Local Phone Number LocalPhoneNumber	934-6467
CY2023	dei	Entity Well Known Seasoned Issuer EntityWellKnownSeasonedIssuer	No
CY2023	dei	Entity Voluntary Filers EntityVoluntaryFilers	No
CY2023	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2023	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2023	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
CY2023	dei	Entity Small Business EntitySmallBusiness	true
CY2023	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	true
CY2023	dei	Entity Ex Transition Period EntityExTransitionPeriod	false
CY2023	dei	Icfr Auditor Attestation Flag IcfrAuditorAttestationFlag	false
CY2023	dei	Document Fin Stmt Error Correction Flag DocumentFinStmtErrorCorrectionFlag	false
CY2023	dei	Entity Shell Company EntityShellCompany	false
CY2023Q2	dei	Entity Public Float EntityPublicFloat	28807680	usd
CY2024Q1	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	36089917	shares
CY2023Q4	ecd	Rule10b51 Arr Adopted Flag Rule10b51ArrAdoptedFlag	false
CY2023Q4	ecd	Non Rule10b51 Arr Adopted Flag NonRule10b51ArrAdoptedFlag	false
CY2023Q4	ecd	Rule10b51 Arr Trmntd Flag Rule10b51ArrTrmntdFlag	false
CY2023Q4	ecd	Non Rule10b51 Arr Trmntd Flag NonRule10b51ArrTrmntdFlag	false
CY2023	dei	Auditor Firm AuditorFirmId	76
CY2023	dei	Auditor Name AuditorName	Turner, Stone & Company, LLP
CY2023	dei	Auditor Location AuditorLocation	Dallas, Texas
CY2023Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	0	usd
CY2022Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	8075	usd
CY2023Q4	us-gaap	Notes Receivable Net NotesReceivableNet	3500000	usd
CY2022Q4	us-gaap	Notes Receivable Net NotesReceivableNet	0	usd
CY2023Q4	us-gaap	Interest Receivable InterestReceivable	38978	usd
CY2022Q4	us-gaap	Interest Receivable InterestReceivable	0	usd
CY2023Q4	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	241601	usd
CY2022Q4	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	142356	usd
CY2023Q4	us-gaap	Assets Current AssetsCurrent	5249713	usd
CY2022Q4	us-gaap	Assets Current AssetsCurrent	3941733	usd
CY2023Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	25237	usd
CY2022Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	25237	usd
CY2023Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	13931	usd
CY2022Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	12695	usd
CY2023Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	11306	usd
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	12542	usd
CY2023Q4	us-gaap	Prepaid Expense Noncurrent PrepaidExpenseNoncurrent	158333	usd
CY2022Q4	us-gaap	Prepaid Expense Noncurrent PrepaidExpenseNoncurrent	348333	usd
CY2023Q4	us-gaap	Finite Lived Contractual Rights Gross FiniteLivedContractualRightsGross	2554166	usd
CY2022Q4	us-gaap	Finite Lived Contractual Rights Gross FiniteLivedContractualRightsGross	3554167	usd
CY2023Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	97571	usd
CY2022Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	58914	usd
CY2023Q4	us-gaap	Other Assets OtherAssets	2810070	usd
CY2022Q4	us-gaap	Other Assets OtherAssets	3961414	usd
CY2023Q4	us-gaap	Assets Assets	8071089	usd
CY2022Q4	us-gaap	Assets Assets	7915689	usd
CY2023Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	1419699	usd
CY2022Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	99021	usd
CY2023Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	555950	usd
CY2022Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	181998	usd
CY2023Q4	us-gaap	Notes Payable Current NotesPayableCurrent	975000	usd
CY2022Q4	us-gaap	Notes Payable Current NotesPayableCurrent	1850000	usd
CY2023Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	38047	usd
CY2022Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	41618	usd
CY2023Q4	us-gaap	Liabilities Current LiabilitiesCurrent	2988696	usd
CY2022Q4	us-gaap	Liabilities Current LiabilitiesCurrent	2172637	usd
CY2023Q4	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	150000	usd
CY2022Q4	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	150000	usd
CY2023Q4	us-gaap	Derivative Liabilities Noncurrent DerivativeLiabilitiesNoncurrent	557250	usd
CY2022Q4	us-gaap	Derivative Liabilities Noncurrent DerivativeLiabilitiesNoncurrent	1125000	usd
CY2023Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	61179	usd
CY2022Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	14723	usd
CY2023Q4	us-gaap	Liabilities Noncurrent LiabilitiesNoncurrent	768429	usd
CY2022Q4	us-gaap	Liabilities Noncurrent LiabilitiesNoncurrent	1289723	usd
CY2023Q4	us-gaap	Liabilities Liabilities	3757125	usd
CY2022Q4	us-gaap	Liabilities Liabilities	3462360	usd
CY2023Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2022Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2023Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	150000000	shares
CY2022Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	150000000	shares
CY2023Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	35331036	shares
CY2023Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	35331036	shares
CY2023Q4	us-gaap	Common Stock Value CommonStockValue	3533	usd
CY2022Q4	us-gaap	Common Stock Value CommonStockValue	1957	usd
CY2023Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	91666691	usd
CY2022Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	70541095	usd
CY2023Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-87356260	usd
CY2022Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-66089723	usd
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	4313964	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	4453329	usd
CY2023Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	8071089	usd
CY2022Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	7915689	usd
CY2023	us-gaap	Revenues Revenues	0	usd
CY2022	us-gaap	Revenues Revenues	0	usd
CY2023	us-gaap	Cost Of Revenue CostOfRevenue	0	usd
CY2022	us-gaap	Cost Of Revenue CostOfRevenue	0	usd
CY2023	us-gaap	Gross Profit GrossProfit	0	usd
CY2022	us-gaap	Gross Profit GrossProfit	0	usd
CY2023	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	6668244	usd
CY2022	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	20887	usd
CY2023	us-gaap	Professional And Contract Services Expense ProfessionalAndContractServicesExpense	10864640	usd
CY2023	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	3945531	usd
CY2023	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	12710	usd
CY2022	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	8331	usd
CY2023	us-gaap	Operating Expenses OperatingExpenses	21491125	usd
CY2022	us-gaap	Operating Expenses OperatingExpenses	34195964	usd
CY2023	us-gaap	Operating Income Loss OperatingIncomeLoss	-21491125	usd
CY2022	us-gaap	Operating Income Loss OperatingIncomeLoss	-34195964	usd
CY2023	us-gaap	Royalty Expense RoyaltyExpense	15000	usd
CY2022	us-gaap	Royalty Expense RoyaltyExpense	90000	usd
CY2023	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-220477	usd
CY2022	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	98701	usd
CY2023	us-gaap	Gains Losses On Extinguishment Of Debt Before Write Off Of Deferred Debt Issuance Cost GainsLossesOnExtinguishmentOfDebtBeforeWriteOffOfDeferredDebtIssuanceCost	0	usd
CY2022	us-gaap	Gains Losses On Extinguishment Of Debt Before Write Off Of Deferred Debt Issuance Cost GainsLossesOnExtinguishmentOfDebtBeforeWriteOffOfDeferredDebtIssuanceCost	-3393542	usd
CY2023	coep	Gain Loss On Change In Fair Value Of Derivative Liability Warrants GainLossOnChangeInFairValueOfDerivativeLiabilityWarrants	567750	usd
CY2022	coep	Gain Loss On Change In Fair Value Of Derivative Liability Warrants GainLossOnChangeInFairValueOfDerivativeLiabilityWarrants	0	usd
CY2023	coep	Gain On Write Down Of Liabilities GainOnWriteDownOfLiabilities	0	usd
CY2022	coep	Gain On Write Down Of Liabilities GainOnWriteDownOfLiabilities	225000	usd
CY2023	us-gaap	Interest Expense InterestExpense	107685	usd
CY2022	us-gaap	Interest Expense InterestExpense	218412	usd
CY2023	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	224588	usd
CY2022	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-3378253	usd
CY2023	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-21266537	usd
CY2022	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-37574217	usd
CY2023	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	usd
CY2022	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	usd
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-21266537	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-37574217	usd
CY2023	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.83
CY2023	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.83
CY2022	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-2.63
CY2022	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-2.63
CY2023	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	25689989	shares
CY2023	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	25689989	shares
CY2022	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	14295678	shares
CY2022	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	14295678	shares
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	2350634	usd
CY2022	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	3271486	usd
CY2022	us-gaap	Stock Issued During Period Value Issued For Services StockIssuedDuringPeriodValueIssuedForServices	4983500	usd
CY2022	us-gaap	Stock Issued During Period Value Conversion Of Convertible Securities StockIssuedDuringPeriodValueConversionOfConvertibleSecurities	5247649	usd
CY2022	us-gaap	Adjustments To Additional Paid In Capital Warrant Issued AdjustmentsToAdditionalPaidInCapitalWarrantIssued	23730298	usd
CY2022	coep	Warrants Issued For Extinguishment Of Debt WarrantsIssuedForExtinguishmentOfDebt	3408559	usd
CY2022	coep	Stock Issued During Period Value Merger StockIssuedDuringPeriodValueMerger	-964580	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-37574217	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	4453329	usd
CY2023	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	500000	usd
CY2023	coep	Shares Issued In Exchange For Note Receivable SharesIssuedInExchangeForNoteReceivable	2500000	usd
CY2023	us-gaap	Stock Issued During Period Value Issued For Services StockIssuedDuringPeriodValueIssuedForServices	4421214	usd
CY2023	us-gaap	Adjustments To Additional Paid In Capital Warrant Issued AdjustmentsToAdditionalPaidInCapitalWarrantIssued	2613183	usd
CY2023	coep	Stock Issued During Period Value Warrants Issued For Cash StockIssuedDuringPeriodValueWarrantsIssuedForCash	200000	usd
CY2023	coep	Warrants Issued In Exchange For Note Receivable WarrantsIssuedInExchangeForNoteReceivable	1000000	usd
CY2023	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	477503	usd
CY2023	coep	Issuance Of Common Stock And Warrants Net Of Issuance Costs IssuanceOfCommonStockAndWarrantsNetOfIssuanceCosts	4792346	usd
CY2023	coep	Shares Issued For Conversion Of Debt SharesIssuedForConversionOfDebt	302926	usd
CY2023	us-gaap	Stock Issued During Period Value Purchase Of Assets StockIssuedDuringPeriodValuePurchaseOfAssets	4320000	usd
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-21266537	usd
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	4313964	usd
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-21266537	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-37574217	usd
CY2023	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	1001237	usd
CY2022	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	1001384	usd
CY2023	us-gaap	Issuance Of Stock And Warrants For Services Or Claims IssuanceOfStockAndWarrantsForServicesOrClaims	4421214	usd
CY2022	us-gaap	Issuance Of Stock And Warrants For Services Or Claims IssuanceOfStockAndWarrantsForServicesOrClaims	4983500	usd
CY2023	us-gaap	Share Based Compensation ShareBasedCompensation	477503	usd
CY2022	us-gaap	Share Based Compensation ShareBasedCompensation	0	usd
CY2023	coep	Warrants Issued For Services WarrantsIssuedForServices	2613183	usd
CY2022	coep	Warrants Issued For Services WarrantsIssuedForServices	23730298	usd
CY2023	coep	Warrants Issued For Extinguishment Of Debt Cash Flow WarrantsIssuedForExtinguishmentOfDebtCashFlow	0	usd
CY2022	coep	Warrants Issued For Extinguishment Of Debt Cash Flow WarrantsIssuedForExtinguishmentOfDebtCashFlow	3408559	usd
CY2023	us-gaap	Derivative Gain Loss On Derivative Net DerivativeGainLossOnDerivativeNet	567750	usd
CY2022	us-gaap	Derivative Gain Loss On Derivative Net DerivativeGainLossOnDerivativeNet	-1125000	usd
CY2023	coep	Shares Issued In Connection With Asset Purchase Agreements SharesIssuedInConnectionWithAssetPurchaseAgreements	4320000	usd
CY2022	coep	Shares Issued In Connection With Asset Purchase Agreements SharesIssuedInConnectionWithAssetPurchaseAgreements	0	usd
CY2023	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-8075	usd
CY2022	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	8075	usd
CY2023	us-gaap	Increase Decrease In Interest Payable Net IncreaseDecreaseInInterestPayableNet	-38978	usd
CY2022	us-gaap	Increase Decrease In Interest Payable Net IncreaseDecreaseInInterestPayableNet	0	usd
CY2023	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	4228	usd
CY2022	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	628	usd
CY2023	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-90755	usd
CY2022	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	490689	usd
CY2023	us-gaap	Increase Decrease In Other Accounts Payable IncreaseDecreaseInOtherAccountsPayable	1320678	usd
CY2022	us-gaap	Increase Decrease In Other Accounts Payable IncreaseDecreaseInOtherAccountsPayable	-35071	usd
CY2023	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	376878	usd
CY2022	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	-17128	usd
CY2023	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-7239514	usd
CY2022	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-3875811	usd
CY2023	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	0	usd
CY2022	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	0	usd
CY2023	us-gaap	Proceeds From Notes Payable ProceedsFromNotesPayable	650000	usd
CY2022	us-gaap	Proceeds From Notes Payable ProceedsFromNotesPayable	0	usd
CY2023	us-gaap	Repayments Of Notes Payable RepaymentsOfNotesPayable	1225000	usd
CY2022	us-gaap	Repayments Of Notes Payable RepaymentsOfNotesPayable	2417000	usd
CY2023	coep	Cash Paid For Debt As Part Of Merger Rec CashPaidForDebtAsPartOfMergerRec	-0	usd
CY2022	coep	Cash Paid For Debt As Part Of Merger Rec CashPaidForDebtAsPartOfMergerRec	614580	usd
CY2023	coep	Proceeds From Issuance Of Common Stock And Warrants Net Of Issuance Costs ProceedsFromIssuanceOfCommonStockAndWarrantsNetOfIssuanceCosts	4792346	usd
CY2022	coep	Proceeds From Issuance Of Common Stock And Warrants Net Of Issuance Costs ProceedsFromIssuanceOfCommonStockAndWarrantsNetOfIssuanceCosts	0	usd
CY2022	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	5487555	usd
CY2023	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect	-2322168	usd
CY2023	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	500000	usd
CY2022	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	3271486	usd
CY2023	coep	Shares Issued For Cash For Conversion Warrants SharesIssuedForCashForConversionWarrants	0	usd
CY2022	coep	Shares Issued For Cash For Conversion Warrants SharesIssuedForCashForConversionWarrants	5247649	usd
CY2023	us-gaap	Proceeds From Issuance Of Warrants ProceedsFromIssuanceOfWarrants	200000	usd
CY2022	us-gaap	Proceeds From Issuance Of Warrants ProceedsFromIssuanceOfWarrants	0	usd
CY2023	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	4917346	usd
CY2022	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect	1611744	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	3791302	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	2179558	usd
CY2023Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	1469134	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	3791302	usd
CY2023	us-gaap	Interest Paid Net InterestPaidNet	0	usd
CY2022	us-gaap	Interest Paid Net InterestPaidNet	0	usd
CY2023	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	0	usd
CY2022	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	0	usd
CY2023	coep	Shares And Warrants Issued In Exchange For Notes Receivable SharesAndWarrantsIssuedInExchangeForNotesReceivable	3500000	usd
CY2022	coep	Shares And Warrants Issued In Exchange For Notes Receivable SharesAndWarrantsIssuedInExchangeForNotesReceivable	0	usd
CY2023	coep	Shares Issued For The Conversion Of Debt SharesIssuedForTheConversionOfDebt	302926	usd
CY2022	coep	Shares Issued For The Conversion Of Debt SharesIssuedForTheConversionOfDebt	0	usd
CY2023Q4	us-gaap	Cash Uninsured Amount CashUninsuredAmount	1219000	usd
CY2022Q4	us-gaap	Cash Uninsured Amount CashUninsuredAmount	3541000	usd
CY2023	us-gaap	Depreciation And Amortization DepreciationAndAmortization	1235	usd
CY2022	us-gaap	Depreciation And Amortization DepreciationAndAmortization	1384	usd
CY2023	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	6668244	usd
CY2022	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	20887	usd
CY2023	us-gaap	Asset Impairment Charges AssetImpairmentCharges	0	usd
CY2022	us-gaap	Asset Impairment Charges AssetImpairmentCharges	0	usd
CY2023Q4	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Four LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour	1420	usd
CY2023Q4	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Five LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive	3256	usd
CY2023Q4	us-gaap	Long Term Debt Maturities Repayments Of Principal After Year Five LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive	145324	usd
CY2023Q4	us-gaap	Long Term Debt LongTermDebt	1125000	usd
CY2023Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	0	usd
CY2022Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	0	usd
CY2023	us-gaap	Use Of Estimates UseOfEstimates	<p id="xdx_843_eus-gaap--UseOfEstimates_zKmF542WwjT9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><span id="xdx_860_zd3TgWRGUYZ7">Use of Estimates</span></b> - The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p>
CY2023Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-87356260	usd
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-21266537	usd
CY2023Q4	us-gaap	Convertible Notes Payable ConvertibleNotesPayable	625000	usd
CY2022Q4	us-gaap	Convertible Notes Payable ConvertibleNotesPayable	1500000	usd
CY2023Q4	us-gaap	Long Term Debt Maturities Repayments Of Principal In Next Twelve Months LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths	975000	usd
CY2023Q4	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Two LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo	0	usd
CY2023Q4	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Three LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree	0	usd
CY2023Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000	shares
CY2023Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2023Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	35331036	shares
CY2023Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	35331036	shares
CY2022Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	19566839	shares
CY2022Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	19566839	shares
CY2023	us-gaap	Adjustments To Additional Paid In Capital Other AdjustmentsToAdditionalPaidInCapitalOther	499950	usd
CY2022	us-gaap	Adjustments To Additional Paid In Capital Other AdjustmentsToAdditionalPaidInCapitalOther	3271445	usd
CY2023	us-gaap	Partners Capital Account Distributions PartnersCapitalAccountDistributions	0	usd
CY2022	us-gaap	Partners Capital Account Distributions PartnersCapitalAccountDistributions	0	usd
CY2023Q2	coep	Warrants Issued WarrantsIssued	2150000	shares
CY2023Q4	us-gaap	Treasury Stock Value TreasuryStockValue	0	usd
CY2022Q4	us-gaap	Treasury Stock Value TreasuryStockValue	0	usd
CY2023Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2023Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2022Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2022Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2023Q4	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions	1223502	usd
CY2023Q4	us-gaap	Deferred Tax Assets In Process Research And Development DeferredTaxAssetsInProcessResearchAndDevelopment	1799825	usd
CY2022Q4	us-gaap	Deferred Tax Assets In Process Research And Development DeferredTaxAssetsInProcessResearchAndDevelopment	0	usd
CY2023Q4	us-gaap	Deferred Tax Assets Property Plant And Equipment DeferredTaxAssetsPropertyPlantAndEquipment	416708	usd
CY2022Q4	us-gaap	Deferred Tax Assets Property Plant And Equipment DeferredTaxAssetsPropertyPlantAndEquipment	0	usd
CY2023Q4	us-gaap	Deferred Tax Assets State Taxes DeferredTaxAssetsStateTaxes	1554275	usd
CY2022Q4	us-gaap	Deferred Tax Assets State Taxes DeferredTaxAssetsStateTaxes	-0	usd
CY2023Q4	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	13232043	shares
CY2022Q4	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	1563911	shares
CY2023	us-gaap	Payments For Rent PaymentsForRent	3750	usd
CY2023	us-gaap	Operating Lease Expense OperatingLeaseExpense	45000	usd
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	45385	usd
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	46046	usd
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	23161	usd
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	114592	usd
CY2023Q4	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	15366	usd
CY2023Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	99226	usd
CY2023Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	97571	usd
CY2023Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	38047	usd
CY2023Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	61179	usd
CY2023Q3	coep	Agreement Amendment Fee AgreementAmendmentFee	2000	usd
CY2023	us-gaap	Defined Benefit Plan Contributions By Employer DefinedBenefitPlanContributionsByEmployer	0	usd
CY2022	us-gaap	Defined Benefit Plan Contributions By Employer DefinedBenefitPlanContributionsByEmployer	0	usd
CY2023Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	23135970	usd
CY2023	us-gaap	Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate	4357970	usd
CY2022	us-gaap	Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate	11648000	usd
CY2023	us-gaap	Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance	4357970	usd
CY2022	us-gaap	Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance	11648000	usd
CY2023	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	usd
CY2023	coep	Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate1 IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate1	2965619	usd
CY2023	coep	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate1 EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate1	0.210	pure
CY2022	coep	Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate1 IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate1	7906850	usd
CY2022	coep	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate1 EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate1	0.210	pure
CY2023	us-gaap	Income Tax Reconciliation State And Local Income Taxes IncomeTaxReconciliationStateAndLocalIncomeTaxes	1392351	usd
CY2023	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	0.090	pure
CY2022	us-gaap	Income Tax Reconciliation State And Local Income Taxes IncomeTaxReconciliationStateAndLocalIncomeTaxes	3765167	usd
CY2022	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	0.100	pure
CY2023	us-gaap	Income Tax Reconciliation Other Adjustments IncomeTaxReconciliationOtherAdjustments	0	usd
CY2023	us-gaap	Effective Income Tax Rate Reconciliation Other Adjustments EffectiveIncomeTaxRateReconciliationOtherAdjustments	0	pure
CY2022	us-gaap	Income Tax Reconciliation Other Adjustments IncomeTaxReconciliationOtherAdjustments	24017	usd
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Other Adjustments EffectiveIncomeTaxRateReconciliationOtherAdjustments	0.002	pure
CY2023	us-gaap	Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate	4357970	usd
CY2023	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.300	pure
CY2022	us-gaap	Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate	11648000	usd
CY2022	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.308	pure
CY2023	us-gaap	Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance	4357970	usd
CY2023	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	0.300	pure
CY2022	us-gaap	Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance	11648000	usd
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	0.308	pure
CY2023	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	usd
CY2023	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0	pure
CY2022	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	usd
CY2022	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0	pure
CY2023Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	22473712	usd
CY2022Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	18429000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Capital Loss Carryforwards DeferredTaxAssetsCapitalLossCarryforwards	0	usd
CY2022Q4	us-gaap	Deferred Tax Assets Capital Loss Carryforwards DeferredTaxAssetsCapitalLossCarryforwards	349000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	18778000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	23135970	usd
CY2022Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	18778000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet	0	usd
CY2022Q4	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet	0	usd
CY2023Q4	us-gaap	Operating Loss Carryforwards OperatingLossCarryforwards	75000000	usd

Files In Submission

Name	View Source	Status
0001683168-24-001685-index-headers.html	Edgar Link	pending
0001683168-24-001685-index.html	Edgar Link	pending
0001683168-24-001685.txt	Edgar Link	pending
0001683168-24-001685-xbrl.zip	Edgar Link	pending
coep-20231231.xsd	Edgar Link	pending
coeptis_ex2101.htm	Edgar Link	pending
coeptis_ex3101.htm	Edgar Link	pending
coep-20231231_def.xml	Edgar Link	unprocessable
coep-20231231_lab.xml	Edgar Link	unprocessable
coep-20231231_pre.xml	Edgar Link	unprocessable
coeptis_ex3102.htm	Edgar Link	pending
coeptis_ex3201.htm	Edgar Link	pending
coeptis_ex3202.htm	Edgar Link	pending
coeptis_i10k-123123.htm	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
image_007.jpg	Edgar Link	pending
image_008.jpg	Edgar Link	pending
image_009.jpg	Edgar Link	pending
image_010.jpg	Edgar Link	pending
image_011.jpg	Edgar Link	pending
image_012.jpg	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
coeptis_i10k-123123_htm.xml	Edgar Link	completed
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
coep-20231231_cal.xml	Edgar Link	unprocessable

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$COEP
Coeptis Therapeutics Holdings, Inc. Stock $coep

2024 Q1 Form 10-K Financial Statement

#000168316824001685 Filed on March 26, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$COEP Coeptis Therapeutics Holdings, Inc. Stock $coep

2024 Q1 Form 10-K Financial Statement

#000168316824001685 Filed on March 26, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$COEP
Coeptis Therapeutics Holdings, Inc. Stock $coep